The Genome Aggregation Database (gnomAD) Consortium has released seven papers leveraging its database to study genetic variants and their potential for guiding discovery of safer drugs.
List view / Grid view
Filter the results
Collaboration between scientists, illustrators and simulators has culminated in highly detailed three-dimensional (3D) models of SARS-CoV-2.
Scientists have designed a high affinity antibody for pathogenic amyloid beta oligomers, a key driver of Alzheimer’s disease, for use in further research and as a potential diagnostic tool.
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Scientists have developed a method for designing artificial proteins that tell the immune system which antibodies to produce so could enhance vaccine design.
Researchers are utilising computers to aid in their investigations into a COVID-19 treatment. Here, we highlight three studies using simulations, calculations and AI to identify a drug to combat the coronavirus.
The COVID-19 Protein Portal, established by UKRI and Wellcome, will allow scientists in the UK to access protein reagents needed for research.
A novel software made by scientists can be used for the analysis of specific lipid groups and lipid signal molecules which can enable their characterisation with mass spectrometry.
A new AI tool has been created by researchers to identify the best treatment courses and doses for bacterial or viral infections, such as COVID-19.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
The enterprise revealed that it has made its COVID-19 Drug Repurposing Database open-access to aid in the search for an effective therapeutic.
Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.